Full-Time

Quality Assurance Specialist 2

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$67k - $83k/yr

Albany, NY, USA

In Person

Bachelor's, Master's

Category
QA & Testing

Get referred to Curia

See people who can refer or advise you

Requirements
  • BA/BS Degree in Chemistry or a relevant field and 3 years of related work experience in pharmaceutical, biotechnology, medical device, and/or cGMP FDA-regulated industry
  • MA/MS Degree in Chemistry or a relevant field and 1 year of related work experience in pharmaceutical, biotechnology, medical device, and/or cGMP FDA-regulated industry
  • Excellent written and verbal presentation and communication skills
  • Strong facilitation skills
  • Strong problem-solving skills, with the ability to resolve conflict
  • Ability to effectively present information to management and/or peers
  • Comfortable working independently and proactively in combination with individuals in other departments across the organization
  • Focused self-starter with attention to detail and ability to multi-task
  • Strong familiarity with the regulatory requirements of ICH Q7, Q9, Q10, and/or 21CFR210 and 211
  • Working knowledge of Microsoft Office or other software as needed
  • Must pass a background check
  • Must pass a drug screen
  • May be required to pass Occupational Health Screening
Responsibilities
  • Represent Curia Quality Assurance when managing issues that require immediate corrective action. Ensure such action taken is appropriate and correctly documented
  • Review quality control testing for compliance with internal SOPs and specifications
  • Report back to appropriate management as to personnel performance, highlighting those areas and individuals in need of improvement as well as those exceeding expectations
  • Author, review, and/or approve Quality Management System documents, including, but not limited to, change controls, SOPs, deviations, CAPAs, etc.
  • Perform and/or participate in internal audits, external audits, investigations, and/or inspections
  • With supervision, may respond or manage responses to clients regarding manufacturing, testing and/or documentation issues
  • May develop and/or maintain Quality System metrics for management review
  • Provide on the floor support to operations, including coordinating and performing day to day activities as needed
  • May assist in developing and conducting training of personnel to execute production in full accordance with cGMP’s and Curia’s quality system to ensure real-time compliance
  • May perform QA visual inspection activities when required
  • Participate in regulatory and client audits
  • Other duties as assigned.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Albuquerque’s $200 million expansion adds commercial drug-product capacity during 2025-2026.
  • Glasgow’s upgrade reaches early 2027, expanding batches to 20,000 vials.
  • March 2025 refinancing and July 2026 recapitalization inject capital for near-term execution.

What critics are saying

  • Apollo-led recapitalization on July 8, 2026 signals strained leverage and lender control.
  • Curia will close Burlington by June 1, 2026, cutting 81 jobs and shrinking capacity.
  • Octus reported June 2, 2026 out-of-court restructuring talks; a failed process risks insolvency.

What makes Curia unique

  • Curia spans discovery through commercial fill-finish across 20+ sites, rare among CDMOs.
  • Glasgow and Albuquerque expansions deepen sterile injectables capacity, including Annex 1 isolator lines.
  • Hopkinton CLD upgrades deliver sixfold higher titers, strengthening biologics process-development economics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.